아시아 태평양 약물 지원 치료(MAT) 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 약물 지원 치료(MAT) 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 231
  • 그림 수: 53

>아시아 태평양 약물 지원 치료(MAT) 시장, 유형(약물 및 요법), 제품(부프레노르핀 및 날록손, 날트렉손, 부프레노르핀, 메타돈, 날록손, 디술피람 및 아캄프로세이트), 약물 유형(제네릭 및 브랜드), 투여 형태(즉시 방출 및 지속 방출), 투여 경로(경구, 비경구 및 기타), 인구 유형(성인 및 청소년), 최종 사용자(재활 클리닉, 병원, 전문 센터, 홈 케어 및 기타) 유통 채널(병원 약국, 직접 입찰, 소매 약국, 온라인 약국 및 기타), 2029년까지의 산업 동향 및 예측

약물 지원 치료(MAT) 시장

시장 분석 및 통찰력

식품의약국(FDA)은 부프레노르핀, 메타돈, 날트렉손의 세 가지 임상 약물을 승인했습니다. 약물 지원 치료(MAT)는 알코올 사용 장애, 오피오이드 의존성 약물, 오피오이드 과용 예방 약물을 치료하는 데 적용됩니다. 알코올 사용 장애(AUD)는 사회적, 직업적 또는 건강적 결과에도 불구하고 알코올 사용을 중단하는 능력이 손상된 의학적 상태입니다. 아캄프로세이트, 디술피람, 날트렉손은 알코올 사용 장애(AUD)를 치료하는 데 가장 일반적으로 사용되는 약물입니다. 오피오이드 의존성 약물은 환자들 사이에서 오피오이드 중독을 증가시킵니다. 부프레노르핀, 메타돈, 날트렉손은 헤로인, 모르핀, 코데인과 같은 단기 작용 오피오이드와 옥시코돈 및 하이드로코돈과 같은 반합성 오피오이드에 대한 오피오이드 사용 장애를 치료하는 데 사용됩니다. 이러한 MAT 약물은 몇 개월, 몇 년 또는 평생 동안 안전합니다 .

약물 지원 치료(MAT) 시장

약물 지원 치료(MAT) 시장

시장 정의

약물 지원 치료(MAT)는 약물을 사용하여 상담 및 행동 치료와 결합하여 물질 사용 장애 치료에 대한 완전한 환자 접근 방식을 제공하는 것을 포함합니다. MAT는 주로 헤로인 및 처방 진통제와 같은 오피오이드 중독을 치료하는 데 사용됩니다. MAT의 목적은 적절한 회복이며, 여기에는 환자 생존율 향상, 치료 유지율 증가, 불법적 반응 감소, 여성의 임신 결과 증가가 포함됩니다. 오피오이드 과용 예방 약물의 경우, 나록손은 과용의 독성 효과를 역전시켜 오피오이드 과용을 예방하는 데 사용됩니다. 세계보건기구(WHO)와 약물 남용 및 정신 건강 서비스청(SAMHSA)에 따르면 나록손은 기능하는 의료 시스템에 필수적인 것으로 간주되는 많은 약물 중 하나입니다.

아시아 태평양 약물 지원 치료는 지지적이며 증상의 심각성을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 약물 지원 치료(MAT) 시장이 2022년부터 2029년까지 10.5%의 CAGR로 성장할 것이라고 분석합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020 (2019-2014까지 사용자 정의 가능)

양적 단위

수익은 백만 달러, 가격은 미화로 표시됨

다루는 세그먼트

 By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others)

Countries Covered

China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific.

Market Players Covered

Indivior PLC, Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Pfizer Inc., Glenmark Pharmaceutical Inc., Viatris Inc., Alvogen, Accord Healthcare, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd.Amneal Pharmaceuticals LLC. among others

Asia-Pacific Medication-Assisted Treatment (MAT) Market Dynamics

Drivers

  • The Rise In The Incidence Of Opioid Use Disorders (Opioid Dependency Medication)

Medication-assisted treatment (MAT) is using medications in combination with counseling and behavioral therapies to provide a "whole-patient" approach to treating substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA), and MAT programs are clinically driven and tailored to meet each patient's needs.

For instance,

  • The prevalence of high-risk opioid use (by injection or long duration/regular use) among adults (aged 15–64) in Asia-Pacific has been relatively stable for many years, with estimates of users standing at around 0.35 % of the EU population

As the companies are constantly engaged in research and developmental activities, the knowledge about the incidence of alcohol use disorder and opioid use disorders would help find novel solutions and aid in more collaborations. This signifies the increase in research and development-related investments for initiating generic medications in medication-assisted treatment (MAT), which is expected to boost the market growth.

  • The Funding By The Government For Medication-Assisted Treatment (MAT)

Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to implementing medications for addiction treatment (MAT) by specialty treatment programs have been observed. Particular attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries.

For instance,

  • In February 2021, the Integrated Substance Use Disorder Training Program (ISTP) was funded to plan, develop, and operate a 12-month full-time or 24-month half-time training program for nurse practitioners and physician assistants for medication-assisted treatment (MAT). The funding expands the workforce trained to provide care for individuals in need of mental health and opioid use disorder prevention

The funding by the government would result in the patient's safety and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.

Opportunities

  • Rise In Healthcare Expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.

For instance,

  • In March 2020, the data by the National Institute of Health (NIH) state that Medicare spent around USD 829,500 million in 2020, or 20 percent of the total NHE

Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favorable factor. The above are expected to create lucrative medication-assisted treatment (MAT) opportunities.

  • Strategic Initiative By Market Players

The demand for medication-assisted treatment (MAT) has increased in the U.S. and Asia-Pacific due to the timely treatment of chronic conditions. These favourable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

  • In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.

Restraint/Challenge

  • Side Effects Of Drugs Used In Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT) involves the use of medications, collated with counselling and behavioural therapies, to provide a "whole-patient" approach as part of the comprehensive treatment strategy. Therefore, the present high cost is expected to show a descending trend in the future. MAT has been shown to be most effective for treating alcohol and opioid use disorders. However, certain side effects have been reported

For instance,

  • Methadone and buprenorphine, the generic medications are chemically similar to opioids, so their side effects can be similar too. These may include constipation, drowsiness, and dizziness. Some people may experience more severe side effects

The adverse complications reported would lead to a decline in sales of the medicated opioid dependency medications, which would limit the sales of the medicines. In addition, it would affect the reliability of manufacturers involved in this market and hence expected to restrain the market growth.

COVID-19 Impact on the Medication-Assisted Treatment (MAT) Market

During the pandemic, medication-assisted treatment (MAT) remarkably reduces mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for medication-assisted treatment (MAT) in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during COVID-19 medication for opioid use disorder (MOUD) services are vital in addressing the opioid crisis, and COVID-19 has significantly impacted MOUD delivery.

Recent Development

  • In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations

Asia-Pacific Medication-Assisted Treatment (MAT) Market Scope

The medication-assisted treatment (MAT) market is segmented on the basis of eight segments: type, products, drug type, dosage form, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Medication
  • Therapy

On the basis of type the Asia-Pacific medication-assisted treatment (MAT) market is segmented into medication and therapy.

Products

  • Buprenorphine and Naloxone
  • Naltrexone
  • Buprenorphine
  • Methadone
  • Naloxone
  • Disulfiram
  • Acamprosate

아시아 태평양 약물 지원 치료(MAT) 시장은 제품을 기준으로 부프레노르핀 및 날록손, 날트렉손, 부프레노르핀, 메타돈, 날록손, 디술피람 및 아캄프로세이트로 구분됩니다.

약물 유형

아시아 태평양 약물 지원 치료(MAT) 시장은 약물 유형을 기준으로 제네릭과 브랜드 의약품으로 구분됩니다.

투여 형태

  • 즉시 출시
  • 연장 릴리스

아시아 태평양 약물 지원 치료(MAT) 시장은 투여 형태를 기준으로 즉시 방출형과 지속 방출형으로 구분됩니다.

투여 경로

  • 경구
  • 비경구적
  • 기타

투여 경로를 기준으로 아시아 태평양 약물 지원 치료(MAT) 시장은 경구 , 비경구 및 기타로 구분됩니다.

인구 유형

  • 성인
  • 10대

인구 유형을 기준으로 볼 때 아시아 태평양 약물 지원 치료(MAT) 시장은 성인과 청소년으로 구분됩니다.

최종 사용자

  • 재활 클리닉
  • 병원
  • 전문 센터
  • 홈케어
  • 기타

아시아 태평양 약물 지원 치료(MAT) 시장은 최종 사용자를 기준으로 재활 클리닉, 병원, 전문 센터, 재택 치료 및 기타로 구분됩니다.

유통 채널

  • 병원 약국
  • 직접 입찰
  • 소매 약국
  • 온라인 약국
  •  기타

약물 지원 치료(MAT) 시장

아시아 태평양 약물 지원 치료(MAT) 시장은 유통 채널을 기준으로 병원 약국, 직접 입찰, 소매 약국, 온라인 약국 및 기타로 구분됩니다.

약물 지원 치료(MAT) 시장 지역 분석/통찰력

아시아 태평양 약물 지원 치료(MAT) 시장을 분석하고, 위에 참조된 지역, 제품 유형, 응용 프로그램, 워크플로, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

약물 지원 치료(MAT) 시장 보고서에서 다루는 국가는 중국, 일본, 한국, 인도, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남 및 기타 아시아 태평양 지역입니다.

 아시아 태평양 지역에서 알코올 장애 사례가 증가하고 약물 지원 치료(MAT)와 약물 지원 인식 프로그램을 받는 인구가 증가함에 따라 중국이 시장을 장악할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 국내 규정 변경 사항을 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 중요한 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 약물 지원 치료(MAT) 시장 점유율 분석

아시아 태평양 약물 지원 치료(MAT) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 아시아 태평양 지역 입지, 생산 시설 및 생산 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 약물 지원 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

약물 지원 치료(MAT) 시장의 주요 기업으로는 Indivior PLC, Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Pfizer Inc., Glenmark Pharmaceutical Inc., Viatris Inc., Alvogen, Accord Healthcare, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 EPIDEMIOLOGY

4.2 PESTEL

4.3 PORTER'S FIVE FORCES MODEL

4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021)

4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021)

4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021)

4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021)

4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET

5 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS

6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)

6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT)

6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)

6.2 RESTRAINTS

6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT)

6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT)

6.2.3 RISE IN PRODUCT RECALLS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS

6.3.2 RISE IN HEALTHCARE EXPENDITURE

6.4 CHALLENGES

6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT

6.4.2 STRINGENT REGULATIONS

6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT)

7 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 OPIOID DEPENDENCY MEDICATION

7.2.1.1 BUPRENORPHINE AND NALOXONE

7.2.1.2 BUPRENORPHINE

7.2.1.3 METHADONE

7.2.1.4 NALTREXONE

7.2.2 ALCOHOL USE DISORDER MEDICATIONS

7.2.2.1 NALTREXONE

7.2.2.2 DISULFIRAM

7.2.2.3 ACAMPROSATE

7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION

7.2.3.1 NALOXONE

7.3 THERAPY

7.3.1 BEHAVIORAL THERAPY

7.3.2 EDUCATIONAL THERAPY

7.3.3 COUNSELLING

7.3.4 VOCATIONAL THERAPY

7.3.5 OTHERS

8 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS

8.1 OVERVIEW

8.2 BUPRENORPHINE AND NALOXONE

8.3 NALTREXONE

8.4 BUPRENORPHINE

8.5 METHADONE

8.6 NALOXONE

8.7 DISULFIRAM

8.8 ACAMPROSATE

9 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE

9.1 OVERVIEW

9.2 GENERICS

9.3 BRANDED

9.3.1 SUBOXONE

9.3.2 VIVITROL

9.3.3 BUTRANS

9.3.4 ZUBSOLV

9.3.5 PROBUPHINE

9.3.6 OTHERS

10 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 IMMEDIATE RELEASE

10.3 EXTENDED RELEASE

11 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 SUBLINGUAL FILM

11.2.3 OTHERS

11.3 PARENTERAL

11.3.1 SOLUTION

11.3.2 SUSPENSION

11.4 OTHERS

12 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE

12.1 OVERVIEW

12.2 ADULTS

12.3 TEENAGE

13 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER

13.1 OVERVIEW

13.2 REHABILITATION CLINICS

13.3 HOSPITALS

13.4 SPECIALTY CENTERS

13.5 HOMECARE

13.6 OTHERS

14 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 DIRECT TENDER

14.4 RETAIL PHARMACY

14.5 ONLINE PHARMACY

14.6 OTHERS

15 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 CHINA

15.1.2 JAPAN

15.1.3 INDIA

15.1.4 AUSTRALIA

15.1.5 SOUTH KOREA

15.1.6 SINGAPORE

15.1.7 MALAYSIA

15.1.8 THAILAND

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 VIETNAM

15.1.12 REST OF ASIA-PACIFIC

16 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021)

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 INDIVOR PLC (2021)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 VIATRIS INC (2021)

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 ALKERMES (2021)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 PURDUE PHARMA L.P. (2021)

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENTS

18.7 PFIZER (2021)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 GLENMARK PHARMACEUTICAL INC (2021)

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENTS

18.9 DR. REDDY’S LABORATORIES LTD (2021)

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 ALVOGEN (2021)

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENTS

18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS)

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENTS

18.13 AMNEAL PHARMACEUTICALS LLC (2021)

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 AMERICAN ADDICTION CENTERS (2021)

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENTS

18.15 HIKMA PHARMACEUTICALS PLC (2021)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENTS

18.16 LANNETT (2021)

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENT

18.17 MALLINCKRODT (2021)

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021)

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.19 PINNACLE TREATMENT CENTERS

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 RECOVERY CENTERS OF AMERICA

18.20.1 COMPANY SNAPSHOT

18.20.2 PRODUCT PORTFOLIO

18.20.3 RECENT DEVELOPMENTS

18.21 TAJ PHARMACEUTICALS LIMITED

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENTS

18.22 TITAN PHARMACEUTICALS (2021)

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENTS

18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021))

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 ASIA PACIFIC MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 ASIA PACIFIC HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA PACIFIC SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 ASIA PACIFIC HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 ASIA PACIFIC OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 40 ASIA PACIFIC HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 ASIA PACIFIC DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 ASIA PACIFIC RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 ASIA PACIFIC ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 44 ASIA PACIFIC OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 46 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 ASIA-PACIFIC MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 ASIA-PACIFIC OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 ASIA-PACIFIC ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 53 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 54 ASIA-PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 55 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 56 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 57 ASIA-PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 58 ASIA-PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 59 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 60 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 61 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 62 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 CHINA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 CHINA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 CHINA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 CHINA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 CHINA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 69 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 70 CHINA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 71 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 72 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 73 CHINA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 74 CHINA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 75 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 76 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 77 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 JAPAN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 JAPAN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 JAPAN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 JAPAN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 83 JAPAN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 85 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 86 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 87 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 88 JAPAN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 89 JAPAN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 90 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 91 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 92 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 93 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 INDIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 INDIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 INDIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 INDIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 INDIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 99 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 100 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 101 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 102 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 103 INDIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 104 INDIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 105 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 106 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 107 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 108 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 AUSTRALIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 110 AUSTRALIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 111 AUSTRALIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 112 AUSTRALIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 AUSTRALIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 115 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 116 AUSTRALIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 117 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 118 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 119 AUSTRALIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 120 AUSTRALIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 121 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 122 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 123 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 124 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 125 SOUTH KOREA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 126 SOUTH KOREA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 127 SOUTH KOREA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 SOUTH KOREA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 SOUTH KOREA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 131 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 132 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 133 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 134 SOUTH KOREA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 135 SOUTH KOREA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 136 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 137 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 138 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 139 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 SINGAPORE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 141 SINGAPORE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 SINGAPORE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 143 SINGAPORE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 SINGAPORE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 146 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 147 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 148 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 149 SINGAPORE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 150 SINGAPORE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 151 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 152 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 153 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 154 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 155 MALAYSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 MALAYSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 157 MALAYSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 158 MALAYSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 159 MALAYSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 161 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 162 MALAYSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 163 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 164 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 165 MALAYSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 166 MALAYSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 167 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 168 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 169 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 170 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 171 THAILAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 THAILAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 173 THAILAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 174 THAILAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 175 THAILAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 177 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 178 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 179 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 180 THAILAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 181 THAILAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 182 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 183 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 184 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 185 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 INDONESIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 INDONESIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 INDONESIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 189 INDONESIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 190 INDONESIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 191 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 192 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 193 INDONESIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 194 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 195 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 196 INDONESIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 197 INDONESIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 198 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 199 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 200 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 201 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 202 PHILIPPINES MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 203 PHILIPPINES OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 204 PHILIPPINES ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 205 PHILIPPINES OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 206 PHILIPPINES THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 207 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 208 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 209 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 210 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 211 PHILIPPINES ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 212 PHILIPPINES PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 213 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 214 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 215 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 216 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 217 VIETNAM MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 218 VIETNAM OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 219 VIETNAM ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 220 VIETNAM OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 221 VIETNAM THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 222 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 223 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 224 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 225 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 226 VIETNAM ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 227 VIETNAM PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 228 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 229 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 230 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 231 REST OF ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION

FIGURE 2 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID

FIGURE 8 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID

FIGURE 10 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029

FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET

FIGURE 15 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019

FIGURE 16 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021

FIGURE 17 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 18 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021

FIGURE 21 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION)

FIGURE 22 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029)

FIGURE 23 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021

FIGURE 25 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)

FIGURE 26 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 27 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 28 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021

FIGURE 29 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)

FIGURE 30 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 31 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 32 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 33 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 34 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 35 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021

FIGURE 37 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)

FIGURE 38 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029)

FIGURE 39 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 40 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021

FIGURE 41 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 42 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 43 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 45 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 46 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 47 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 49 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)

FIGURE 50 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 51 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 52 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 53 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.